Efti Manufacturing Differences Shape Development Reset
Immutep reported that its continuing review of the discontinued TACTI-004 Phase III trial has identified structural differences between eftilagimod alfa manufactured in 200-liter and 2,000-liter processes, including a subtle N-glycan difference. Earlier Phase I
